Eiger Mountains

Investor Overview

Corporate Profile

Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a...  More >>

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
- First-Ever Phase 3 HDV International D-LIVR Study Enrolling - NDA and MAA filings for Progeria & Progeroid Laminopathies planned for Q4 2019 PALO ALTO, Calif. , Aug. 8, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted
Toggle Summary Eiger BioPharmaceuticals to Participate in Investor Conferences in August
PALO ALTO, Calif. , Aug. 5, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in
Toggle Summary Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)
- Third Eiger Pipeline Program Granted Breakthrough Therapy Designation PALO ALTO, Calif. , June 17, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the
Toggle Summary Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs
PALO ALTO, Calif. , June 10, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach , PhD, RPh as Vice President of Global Regulatory
Upcoming EventsMore >>
Date Title
09/05/19
Location:
Boston

United States


Sunday, September 08, 2019 through Tuesday, September 10, 2019
Location:
NYC

United States


Monday, September 09, 2019 through Wednesday, September 11, 2019
Location:
East, Boston

United States


What's New
There are currently no items available.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site.